This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (32)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in this journal  Topic Collections  • Rheumatology  • Rheumatology, Other  • Immunology  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Guillermo Ruiz-Irastorza, MD, PhD; Maria-Victoria Egurbide, MD; Jon Ugalde, MD; Ciriaco Aguirre, MD, PhD

Arch Intern Med. 2004;164:77-82.

Background  Thrombosis is a frequent cause of morbidity and death in patients with systemic lupus erythematosus (SLE). Whether antiphospholipid syndrome (APS) is the cause of increased irreversible organ damage and mortality in lupus patients is not well established.

Methods  Prospective inception cohort of 202 patients with SLE (American College of Rheumatology criteria). Antiphospholipid syndrome was defined according to the Sapporo criteria. Irreversible damage was measured using the Systemic Lupus International Collaborating Clinics–American College of Rheumatology damage index (SDI) at 6 months and 1, 3, 5, 10, 15, 20, and 25 years after the diagnosis of SLE. All deaths were documented.

Results  A total of 88% of patients were women. Twenty-eight patients met criteria for definite APS. Mean (SD) follow-up was 9.7 (6.0) years. Nine patients could not be contacted for follow-up. All patients with APS experienced thrombosis, most of them in the arterial bed. Damage was more severe in patients with APS than in those without APS (median SDI score, 2 vs 0 at 5 years; P<.001; 4 vs 1 at 15 years; P<.001). Cumulative survival at 15 years was lower in patients with APS than in those without APS (65% vs 90%, P = .03). Older age at diagnosis, lupus nephritis, and APS were independent predictors of mortality.

Conclusions  Antiphospholipid syndrome with thrombotic manifestations is a major predictor of irreversible organ damage and death in patients with SLE.

From the Servicio de Medicina Interna, Hospital de Cruces, Universidad del Pais Vasco/Euskal Herriko Unibertsitatea, Bizkaia, Spain. The authors have no relevant financial interest in this article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Antiphospholipid Testing and Outcome
Christoph Pechlaner and Christian J. Wiedermann
Arch Intern Med. 2004;164(15):1701.
EXTRACT | FULL TEXT  

Antiphospholipid Testing and Outcome—Reply
Guillermo Ruiz-Irastorza, Maria-Victoria Egurbide, and Ciriaco Aguirre
Arch Intern Med. 2004;164(15):1701-1702.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Thrombosis in Systemic Lupus Erythematosus and Other Autoimmune Diseases of Recent Onset
ROMERO-DIAZ et al.
The Journal of Rheumatology 2009;36:68-75.
ABSTRACT | FULL TEXT  

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics
Bertsias et al.
Ann Rheum Dis 2008;67:195-205.
ABSTRACT | FULL TEXT  

Pulmonary and Thrombotic Manifestations of Systemic Lupus Erythematosus
Swigris et al.
Chest 2008;133:271-280.
ABSTRACT | FULL TEXT  

Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus
Martinez-Berriotxoa et al.
Lupus 2007;16:810-816.
ABSTRACT  

Review: Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome
Avcin and Silverman
Lupus 2007;16:627-633.
ABSTRACT  

Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus
Ruiz-Irastorza et al.
Lupus 2006;15:577-583.
ABSTRACT  

Systemic lupus erythematosus.
D'Cruz
BMJ 2006;332:890-894.
FULL TEXT  

High risk of tuberculosis in systemic lupus erythematosus?
Erdozain et al.
Lupus 2006;15:232-235.
ABSTRACT  

Laboratory diagnosis and management challenges in the antiphospholipid syndrome
Bertolaccini and Khamashta
Lupus 2006;15:172-178.
ABSTRACT  

Stroke and antiphospholipid syndrome: the treatment debate
Ruiz-Irastorza and Khamashta
Rheumatology (Oxford) 2005;44:971-974.
ABSTRACT | FULL TEXT  

Renal manifestations of the antiphospholipid syndrome
D'Cruz
Lupus 2005;14:45-48.
ABSTRACT  

Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus
Ruiz-Irastorza et al.
Lupus 2004;13:900-905.
ABSTRACT  

Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus
Martinez-Berriotxoa et al.
Lupus 2004;13:927-933.
ABSTRACT  

Antibodies and clinical features of the antiphospholipid syndrome as criteria for systemic lupus erythematosus
Merrill
Lupus 2004;13:869-876.
ABSTRACT  

Antiphospholipid Testing and Outcome
Pechlaner and Wiedermann
Arch Intern Med 2004;164:1701-1701.
FULL TEXT  

Antiphospholipid Testing and Outcome--Reply
Ruiz-Irastorza et al.
Arch Intern Med 2004;164:1701-1702.
FULL TEXT  

Robin Goodfellow (43-4)
Rheumatology (Oxford) 2004;43:540-540.
FULL TEXT